Clinical trials: Pemphigus
Pemphigus, Pemphigus Vulgaris
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
This was a multicenter, open-label safety study to determine the dose regimen of SYNT001 (ALXN1830) administered intravenously in participants with pemphigus (vulgaris or foliaceus).
- Conditions
- Pemphigus, Pemphigus Vulgaris, Pemphigus Foliaceus
- Trial name
- NCT03075904
- Testing
- ALXN1830
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Pemphigus Foliaceus, Pemphigus Vulgaris
Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus
T cells, a type of white blood cell called a lymphocyte, play an important role in the immune system. One subtype, the regulatory T cell (Treg) helps to regulate the immune system and may provide protection against the…
- Trial name
- NCT03239470
- Testing
- Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus is a severe autoimmune blistering disease mediated by circulating antibodies against certain proteins important for maintaining skin integrity.
- Trial name
- NCT00656656
- Testing
- Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- University of Luebeck
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This was a prospective, multicenter, open label extension (OLE) trial on the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK and PD of efgartigimod PH20 SC in adult PV or PF participants, who…
- Trial name
- ADDRESS+ (NCT04598477)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 127 sites in United States, Australia and 19 more
- Volunteers
- 183 people
- Sponsor
- argenx
Pemphigus Vulgaris
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.
- Trial name
- NCT01920477
- Testing
- Ofatumumab
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Pemphigus
A Study of PRN1008 in Patients With Pemphigus
This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment [BT] period) followed by an open-label extension [OLE] period intended to evaluate the efficacy and safety of oral PRN1008…
- Trial name
- NCT03762265
- Testing
- Rilzabrutinib
- Where
- 88 sites in United States, Argentina and 17 more
- Volunteers
- 131 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Pemphigus Vulgaris
Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus
The purpose of this study is to compare two standard treatments for pemphigus to determine which more effectively improves the clinical manifestations of the disease and decreases serum level of the autoantibodies which cause the…
- Trial name
- NCT00483119
- Testing
- intravenous immunoglobulin, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Pemphigus
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug.
- Trial name
- NCT01313923
- Testing
- Sirolimus (formerly known as Rapamycin)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of California, Irvine
Pemphigus Vulgaris
Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris
The study evaluated the efficacy, safety and pharmacokinetics of VAY736 in the treatment of patients with pemphigus vulagaris (PV).
- Trial name
- NCT01930175
- Testing
- VAY736
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Pemphigus Vulgaris
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue…
- Trial name
- NCT02704429
- Testing
- PRN1008
- Where
- 13 sites in Australia, Croatia and 3 more
- Volunteers
- 42 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Pemphigus
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who…
- Trial name
- NCT02613910
- Testing
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Pemphigus Vulgaris
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active…
- Trial name
- NCT02383589
- Testing
- Mycophenolate Mofetil, Rituximab
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled trial to investigate the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK, and PD of efgartigimod PH20 SC in adult…
- Trial name
- ADDRESS (NCT04598451)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 134 sites in United States, Australia and 19 more
- Volunteers
- 222 people
- Sponsor
- argenx
Asthma
Promoting Risk Reduction Among Young Adults With Asthma During Wildfire Smoke Events (TRAK)
This research will contribute to fundamental knowledge about how young adults with asthma perceive their personal health risks to wildfire smoke, minimize their risk, and improve their health.
- Trial name
- TRAK (NCT04724733)
- Testing
- Smoke Sense, Smoke Sense Plus
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Washington State University
Oral Lichen Planus, Mucous Membrane Pemphigoid
Dexamethasone Solution and Dexamethasone in Mucolox™
Topical steroid therapy is considered the first line of treatment for Oral Inflammatory Ulcerative Diseases with current treatment regimens requiring multiple application or rinses daily.
- Conditions
- Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
- Trial name
- NCT04540133
- Testing
- dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pemphigus
Use of Infliximab for the Treatment of Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare skin disorder that causes blistering of the skin and mucous membranes. Infliximab is a man-made antibody used to treat certain types of immune system disorders, including rheumatoid arthritis and…
- Trial name
- NCT00283712
- Testing
- Infliximab
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)